Neodymium: Yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma

American Journal of Gastroenterology

Volumn 97, Issue 12, 2002, Pages 2998-3006

  Weston, Allan P ^a,b   Sharma, Prateek ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; ECHOGRAPHY; ESOPHAGUS CARCINOMA; ESOPHAGUS STRICTURE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GOBLET CELL; HUMAN; HUMAN TISSUE; MALE; NEODYMIUM LASER; PRIORITY JOURNAL; SAFETY; SQUAMOUS EPITHELIUM; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALUMINUM; BARRETT ESOPHAGUS; BIOPSY; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; LASER SURGERY; MALE; MIDDLE AGED; NEODYMIUM; YTTRIUM;

EID: 0036894963     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)05534-X     Document Type: Article

References (57)

1. Dominitz JA, Provenzale D. Prevalence of dyspepsia, heartburn, and peptic ulcer disease in veterans. Am J Gastroenterol 1999;94:2086-93.
2. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-3.
3. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 1991;20:817-34.
4. Winters CJ, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterol 1987;92:118-24.
5. Sharma P, Reker D, Falk G, et al. Progression of Barrett's esophagus to high-grade dysplasia and cancer: Preliminary results of the BEST (Barrett's Esophagus Study Trial). Gastroenterol 2001;120(suppl 1)A-16 (abstract 79).
6. Altorki NK, Sunagawa M, Skinner DB. High-grade dysplasia in the columnar-lined esophagus. Am J Surg 1991;161:97-100.
7. Pera M, Trastek VF, Carpenter HA, et al. Barrett's esophagus with high-grade dysplasia: An indication for esophagectomy? Ann Thorac Surg 1992;54:199-204.
8. Rice TW, Falk GW, Achkar E, et al. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;88:1832-6.
9. Peters JH, Clark GWB, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-22.
10. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia: An indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
11. Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: Implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997;114:824-9.
12. Cameron AJ Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study. Am J Gastroenterol 1997;92:586-91.
13. Falk GW, Catalano MF, Sivak MV Jr. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. Gastrointestinal Endosc 1994;40:207-12.
14. Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
15. DeMeester TR. Surgical treatment of dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997;26:669-84.
16. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
17. Blount PL, Rabinovitch PS, Reid BJ. DNA content flow cytometry and neoplastic progression in the gastrointestinal tract. In: Eastwood GL, ed. Premalignant conditions of the gastrointestinal tract. Pathogenesis, Diagnosis, and Management. New York: Elsevier, 1990:55-77.
18. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus. Prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
19. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk subsets. Am J Gastroenterol 2000;95:1669-76.
20. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignacy in dysplasia free Barrett's esophagus. Thirteen-year follow-up study of a cohort of patients. Cytometry 1998;34:257-63.
21. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barret's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
22. Menke-Pluymers MBE, Mulder A, Hop WCJ, et al. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. Gut 1994;35:1348-51.
23. Reid BJ, Prevo LJ, Galipeaus BS, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
24. Wong DJ, Paulson TG, Prevo LJ, et al. p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
25. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic and histologic factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999;94:3413-9.
26. Iftokhar SY, James PD, Steele RJC, et al. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
27. Weston AP, Hassanein R, Sharma P. Risk stratification of Barrett's esophagus: Updated prospective multivariate analysis. Am J Gastroenterol 2001;96:S44 (abstract 135).
28. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1864-8.
29. Reid BJ, Haggitt RC, Rubin RC, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
30. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation. Hum Pathol 2001;32:368-78.
31. Sampliner RE. Ablative therapies for the columnar lined esophagus. Gastroenterol Clin North Am 1997;26:685-94.
32. Overholt BF, Panjehpour M. Barrett's esophagus: Photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995;42:64-70.
33. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus: Clinical update. Am J Gastroenterol 1996;91:1719-23.
34. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999;49:S20-3.
35. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: Follow up in 100 patients. Gastrointest Endosc 1999;49:1-7.
36. Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001;54:682-8.
37. Sharma P, Jaffe PE, Bhattacharyya A, et al. Laser and multipolar electrocoagulation ablation of early Barrett's adenocarcinoma: Long-term follow up. Gastrointest Endosc 1999;49:442-6.
38. Yang GR, Zhao LQ, Li SS, et al. Endoscopic Nd:YAG laser therapy in patients with early superficial carcinoma of the esophagus and the gastric cardia. Endoscopy 1994;26:681-5.
39. Ertan A. Zimmerman M, Younes M. Esophageal adenocarcinoma associated with Barrett's esophagus: Long-term management with laser ablation. Am J Gastroenterol 1995;90:2201-3.
40. Sharma P, Jaffe P, Bhattacharyya A, et al. Fate of high grade dysplasia at 1 year after endoscopic ablation with Nd:YAG laser and electrocautery. Am J Gastroenterol 2000;95:79.
41. Scotiniotis IA, Kochman ML, Lewis JD, et al. Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 2001;54:689-96.
42. Soehendra N, Binmoeller KF, Bohnacker S, et al. Endoscopic snare mucosectomy in the esophagus without any additional equipment: A simple technique for resection of flat early cancer. Endoscopy 1997;29:380-3.
43. Weston AP, Sharma P. Enhancement of residual Barrett's tissue during thermal ablation with use of Lugol's iodine chromoendoscopy: A prospective study. Am J Gastroenterol 2000;95:106.
44. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985;110:145-52.
45. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical implications. Hum Pathol 1983;14:931-68.
46. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 1991;20:817-34.
47. Weston AP, Sharma P, Richards R, et al. Long-term follow up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
48. Bronner MP. Columnar lined epithelium and dysplasia - Confirming the diagnosis. In: Boyce HW, ed. Esophagology for Clinicians: Pathophysiology, Diagnosis, and Therapy. Tampa, Florida: University of South Florida, 1999.
49. Lerut T, Coosemans W, Van Raemdonck D, et al. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg 1994;107:1059-65.
50. Steup WH, De Leyn P, Deneffe G, et al. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTMN classification. J Thorac Cardiovasc Surg 1996;111:85-94.
51. Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747-51.
52. Patti MG, Corvera CU, Glasgow RE, et al. Hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998;2:186-92.
53. Levine DS, Management of dysplasia in the columnar lined esophagus. Gastroenterol Clin North Am 1997;26:613-34.
54. Rice TW, Zuccaro G Jr, Adelstein DJ, et al. Depth of tumor invasion (T) is predictive of regional lymph node status (N) for esophageal carcinoma. Ann Thorac Surg 1998;65:787-92.
55. VanLaethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squmaous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574-7.
56. Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd; YAG laser for palliation of esophageal cancer: A multicenter randomized trial. Gastrointest Endosc 1995;42:507-12.
57. Schweitzer VG, Bologna S, Batra SK. Photodynamic therapy for treatment of esophageal cancer: A preliminary report. Laryngoscope 1993;103:699-703.